Poly Medicure Limited

rs,

: - 531768 The Manager, BSE Limited, Department of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, Mumbai- 400001. "; ’ ‘ POLYMED Scrip Code:- POLYMED The Manager National Stock

,%

Updates Standalone Performance Summary Q4 FY26 & 12M FY26 Figs in Rs. Crs unless specified Margin,% Revenue Gross Profit Operating EBITDA1 443.0 1,662.5 295.2 1,070.0 1,132.0 121.1 44

65.8%

0 1,662.5 295.2 1,070.0 1,132.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 F

66.6%

62.5 295.2 1,070.0 1,132.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY

66.8%

295.2 1,070.0 1,132.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4

68.1%

1,070.0 1,132.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q

27.6%

0 1,132.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26

27.3%

32.0 121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25

27.8%

121.1 445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 N

26.8%

445.9 446.1 421.0 1,601.8 277.1 116.2 65.8% 66.6% 66.8% 68.1% 27.6% 27.3% 27.8% 26.8% Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 No of Pa

17.4%

Y25 FY26 Q4 FY25 Q4 FY26 FY25 FY26 No of Patents 348 Cash & Cash Equivalents 796.8 RoCE2 17.4% RoIC3 21.4% • Gross Margin expansion by 130 bps in FY26 led by improving product mix and cost op

21.4%

FY25 Q4 FY26 FY25 FY26 No of Patents 348 Cash & Cash Equivalents 796.8 RoCE2 17.4% RoIC3 21.4% • Gross Margin expansion by 130 bps in FY26 led by improving product mix and cost optimization ini

“unless specified As at Mar 31, 2026 As at Mar 31, 2025 • Given high capex and investment phase 2,744.2 169.9 2,914.1 1,218.8 89.5 63.4 1,542.5 442.9 10.2 (58.9) 394.1 25.6% for Polymed, evaluating business performance on balance sheet level ROCE may not be relevant due to large undeployed capital • Acquisitions made during the FY26 only have contributed partially to the financial performance of FY26.”

“Baid has played a pivotal role in establishing the company’s foundation and continues to provide strategic guidance with an experience of 56 years.”

Less

1

Less

- Cash & Cash equivalent - Assets yet to be capitalized or unutilized* - Investment in Subsidiaries/ associates Invested Capital (A) PBT Interest Expense Income on Liquid Investments (cash and cash equivalents above) EBIT (B) Return on Invested Capital (B/A) *includes CWIP, landbank currently unutilised Figs in Rs. Cr. unless specified As at Mar 31, 2026 As at Mar 31, 2025 • Given high capex and investment phase 2,744.2 169.9 2,914.1 1,218.8 89.5 63.4 1,542.5 442.9 10.2 (58.9) 394.1 25.6% for Polymed, evaluating business performance on balance sheet level ROCE may not be relevant due to large undeployed capital • Acquisitions made during the FY26 only have contributed partially to the financial performance of FY26. • Given above points, computing ROIC (“Return on Invested Capital”) is a better metric to evaluate financial performance • Despite low growth in FY 26, ROIC continues to remain in excess of 20% 3,052.7 248.4 3,301.1 796.8 146.3 503.3 1,854.7 447.9 12.9 (67.3) 393.3 21.4% 15